{"url":"https://nivawealth.com/firms/sr-one-capital-management-306361","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/306361","regulatoryAum":2435935604,"crd":"306361","history":[{"filedOn":"2021-07-15","regulatoryAum":690715171,"clients":1,"employees":13,"offices":2},{"filedOn":"2022-06-14","regulatoryAum":1082375346,"clients":14,"employees":21,"offices":3},{"filedOn":"2023-06-23","regulatoryAum":1432842747,"clients":15,"employees":24,"offices":3},{"filedOn":"2024-07-17","regulatoryAum":1592246090,"clients":17,"employees":24,"offices":3},{"filedOn":"2025-03-31","regulatoryAum":2090103590,"clients":17,"employees":30,"offices":3},{"filedOn":"2026-03-31","regulatoryAum":2435935604,"clients":19,"employees":28,"offices":2}],"secFileNumber":"801-119142","legalName":"SR One Capital Management, LP","displayName":"SR One Capital Management","slug":"sr-one-capital-management-306361","website":"https://srone.com/","logo":{"src":"https://rmkhnxnbeclogprvkfyl.supabase.co/storage/v1/object/public/firm-logos/306361/76360116af398564-r1.webp","tone":"light","width":962,"height":200,"sourceUrl":"https://www.srone.com/","sourceLabel":"SR ONE Capital Management, LP, website"},"classification":{"segment":"private_funds","segmentLabel":"Private funds","type":"private_fund_manager","typeLabel":null,"feeDisclosure":"payment_only"},"founded":null,"organization":"Delaware limited partnership","fiscalYearEnd":"December","headquarters":{"street":"929 Main Street, Suite 200","city":"Redwood City","state":"CA","stateName":"California","country":"United States","postalCode":"94063"},"tradeNames":[],"registration":{"secApproved":"24 July 2020","noticeFilings":null,"latestNoticeFiling":null},"wealthAumPerClient":null,"staff":{"employees":28,"advisory":15,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"regulatory":2435935604,"discretionary":2435935604,"discretionaryAccounts":19,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":0,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":19,"regulatoryAum":2435935604}],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[],"custodyNote":"SR One Capital Management has custody of $2.44B for 19 clients.","otherCustodians":[],"leadership":[{"name":"Rajeev Dadoo","title":"Limited Partner; Managing Partner; COO","crd":"7196490"},{"name":"Simeon George","title":"Limited Partner; CEO; Managing Partner","crd":"7196489"},{"name":"Sasha Keough","title":"CCO","crd":"7682447"},{"name":"James Macadam","title":"CFO","crd":"7719686"}],"ownership":[{"label":"Simeon George","detail":"Limited partner; ceo; managing partner in the 25% to 50% ownership band and a control person, since October 2019. Also a managing member of SR One Capital Management, LLC in the 75% or more band and a control person, since October 2019."},{"label":"Rajeev Dadoo","detail":"Limited partner; managing partner; coo in the 25% to 50% ownership band and a control person, since October 2019."}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":1,"privateResidences":0},"listedOfficeAddresses":2,"foreignOffices":[{"city":"LONDON","country":"United Kingdom","postalCode":"W1G 0QF","street":"6TH FLOOR","display":{"city":"LONDON","region":null,"postalCode":"W1G 0QF","ruleVersion":"office-display-1"}}],"officesByState":[{"state":"California","offices":1,"addresses":[{"street":"929 Main Street, Suite 200","city":"Redwood City","headquarters":true}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"408-303-2673","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":null,"assetMix":[],"privateFunds":19},"sources":{"adv1FilingDate":"31 March 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/306361/PDF/306361.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","updatedOn":"2026-10-21","holdingsUpdatedOn":"2026-10-21","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does SR One Capital Management have?","answer":"SR One Capital Management has 19 clients and manages $2.44 billion for them, as of March 2026. They include 19 pooled investment vehicles.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 31 March 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does SR One Capital Management offer?","answer":"SR One Capital Management provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How many financial advisors does SR One Capital Management have?","answer":"SR One Capital Management has 0 investment adviser representatives registered with state securities authorities, out of 28 employees, and 15 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns SR One Capital Management?","answer":"SR One Capital Management’s direct owners are Simeon George and Rajeev Dadoo, each holding 50% or less.","source":"Form ADV Part 1A, Schedules A and B, filed 31 March 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does SR One Capital Management get paid?","answer":"SR One Capital Management is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How do I contact SR One Capital Management?","answer":"SR One Capital Management’s main office is at 929 Main Street, Suite 200, Redwood City, CA 94063. Its phone number is 408-303-2673. Its website is srone.com.","source":"Form ADV Part 1A, Item 1.F, filed 31 March 2026","sourceRef":{"doc":"adv1","section":"offices"}}],"holdings":{"url":"https://nivawealth.com/firms/sr-one-capital-management-306361/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-12","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1910264/000119312526347065/0001193125-26-347065-index.html","totalValue":1039007705,"positionCount":15,"top10Share":0.9510775023559619,"top10":[{"issuer":"Veradermics, Inc.","titleOfClass":"Common Stock","cusip":"922967104","value":295285652,"shares":2401868,"shareType":"SH","priorValue":151677964,"priorShares":2401868},{"issuer":"Zenas BioPharma, Inc","titleOfClass":"Common Stock","cusip":"98937L105","value":127860735,"shares":5037854,"shareType":"SH","priorValue":98490046,"priorShares":5037854},{"issuer":"CRISPR Therapeutics AG","titleOfClass":"Common Shares","cusip":"H17182108","value":111194134,"shares":2038763,"shareType":"SH","priorValue":96983956,"priorShares":2038763},{"issuer":"Avalyn Pharma, Inc","titleOfClass":"Common Stock","cusip":"05348Y105","value":108920725,"shares":3308649,"shareType":"SH"},{"issuer":"Design Therapeutics, Inc.","titleOfClass":"Common Stock","cusip":"25056L103","value":94438108,"shares":6526476,"shareType":"SH","priorValue":69441704,"priorShares":6526476},{"issuer":"Odyssey Therapeutics, Inc.","titleOfClass":"Common Stock","cusip":"67613T104","value":71002261,"shares":3794883,"shareType":"SH"},{"issuer":"Alumis Inc.","titleOfClass":"Common Stock","cusip":"022307102","value":55151473,"shares":1959896,"shareType":"SH","priorValue":43176509,"priorShares":1959896},{"issuer":"ORIC Pharmaceuticals, Inc.","titleOfClass":"Common Stock","cusip":"68622P109","value":49984609,"shares":4615384,"shareType":"SH","priorValue":58476915,"priorShares":4514929},{"issuer":"Mineralys Therapeutics Inc.","titleOfClass":"Common Stock","cusip":"603170101","value":42195803,"shares":1563966,"shareType":"SH","priorValue":42367839,"priorShares":1563966},{"issuer":"ARS Pharmaceuticals, Inc.","titleOfClass":"Common Stock","cusip":"82835W108","value":32143353,"shares":4012903,"shareType":"SH","priorValue":32223611,"priorShares":4012903}],"positionsListed":15,"positions":[{"issuer":"Veradermics, Inc.","titleOfClass":"Common Stock","cusip":"922967104","value":295285652,"shares":2401868,"shareType":"SH","priorValue":151677964,"priorShares":2401868},{"issuer":"Zenas BioPharma, Inc","titleOfClass":"Common Stock","cusip":"98937L105","value":127860735,"shares":5037854,"shareType":"SH","priorValue":98490046,"priorShares":5037854},{"issuer":"CRISPR Therapeutics AG","titleOfClass":"Common Shares","cusip":"H17182108","value":111194134,"shares":2038763,"shareType":"SH","priorValue":96983956,"priorShares":2038763},{"issuer":"Avalyn Pharma, Inc","titleOfClass":"Common Stock","cusip":"05348Y105","value":108920725,"shares":3308649,"shareType":"SH"},{"issuer":"Design Therapeutics, Inc.","titleOfClass":"Common Stock","cusip":"25056L103","value":94438108,"shares":6526476,"shareType":"SH","priorValue":69441704,"priorShares":6526476},{"issuer":"Odyssey Therapeutics, Inc.","titleOfClass":"Common Stock","cusip":"67613T104","value":71002261,"shares":3794883,"shareType":"SH"},{"issuer":"Alumis Inc.","titleOfClass":"Common Stock","cusip":"022307102","value":55151473,"shares":1959896,"shareType":"SH","priorValue":43176509,"priorShares":1959896},{"issuer":"ORIC Pharmaceuticals, Inc.","titleOfClass":"Common Stock","cusip":"68622P109","value":49984609,"shares":4615384,"shareType":"SH","priorValue":58476915,"priorShares":4514929},{"issuer":"Mineralys Therapeutics Inc.","titleOfClass":"Common Stock","cusip":"603170101","value":42195803,"shares":1563966,"shareType":"SH","priorValue":42367839,"priorShares":1563966},{"issuer":"ARS Pharmaceuticals, Inc.","titleOfClass":"Common Stock","cusip":"82835W108","value":32143353,"shares":4012903,"shareType":"SH","priorValue":32223611,"priorShares":4012903},{"issuer":"Mobia Medical, Inc","titleOfClass":"Common Stock","cusip":"60705V103","value":26613365,"shares":1986072,"shareType":"SH"},{"issuer":"Nkarta, Inc.","titleOfClass":"Common Stock","cusip":"65487U108","value":9433332,"shares":3333333,"shareType":"SH","priorValue":7033333,"priorShares":3333333},{"issuer":"Oculis Holding AG","titleOfClass":"Ordinary Shares","cusip":"H5870P102","value":8890975,"shares":641022,"shareType":"SH","priorValue":17044775,"priorShares":641022},{"issuer":"Ultragenyx Pharmaceutical Inc.","titleOfClass":"Common Stock","cusip":"90400D108","value":4599573,"shares":137753,"shareType":"SH","priorValue":2885925,"priorShares":137753},{"issuer":"enGene Holdings Inc.","titleOfClass":"Common Shares","cusip":"29286M105","value":1293607,"shares":747750,"shareType":"SH","priorValue":5092178,"priorShares":747750}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}